Quidel Co. (NASDAQ:QDEL) Shares Sold by Oak Family Advisors LLC

Oak Family Advisors LLC trimmed its stake in shares of Quidel Co. (NASDAQ:QDELGet Rating) by 44.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,535 shares of the company’s stock after selling 1,251 shares during the period. Oak Family Advisors LLC’s holdings in Quidel were worth $207,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Morgan Stanley grew its holdings in Quidel by 4.8% in the second quarter. Morgan Stanley now owns 124,274 shares of the company’s stock valued at $15,923,000 after purchasing an additional 5,712 shares during the period. Assenagon Asset Management S.A. acquired a new stake in shares of Quidel in the third quarter worth approximately $948,000. Traynor Capital Management Inc. boosted its stake in shares of Quidel by 128.2% in the third quarter. Traynor Capital Management Inc. now owns 8,260 shares of the company’s stock worth $1,165,000 after acquiring an additional 4,640 shares during the last quarter. New York State Teachers Retirement System boosted its stake in shares of Quidel by 3.6% in the third quarter. New York State Teachers Retirement System now owns 55,118 shares of the company’s stock worth $7,780,000 after acquiring an additional 1,938 shares during the last quarter. Finally, First Quadrant L P CA boosted its stake in shares of Quidel by 1,500.0% in the third quarter. First Quadrant L P CA now owns 2,240 shares of the company’s stock worth $316,000 after acquiring an additional 2,100 shares during the last quarter. 85.81% of the stock is currently owned by hedge funds and other institutional investors.

In other news, Director Mary Lake Ph D. Polan sold 1,525 shares of Quidel stock in a transaction on Friday, March 18th. The stock was sold at an average price of $113.59, for a total value of $173,224.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 2.70% of the company’s stock.

A number of brokerages recently commented on QDEL. Raymond James upgraded Quidel from an “outperform” rating to a “strong-buy” rating and reduced their price objective for the stock from $155.00 to $130.00 in a research report on Tuesday, February 22nd. TheStreet downgraded Quidel from a “b-” rating to a “c+” rating in a research report on Thursday, February 10th. Finally, StockNews.com downgraded Quidel from a “buy” rating to a “hold” rating in a research report on Tuesday, April 5th. One research analyst has rated the stock with a hold rating, two have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $142.80.

NASDAQ:QDEL traded down $1.44 on Friday, reaching $116.20. The company’s stock had a trading volume of 557,874 shares, compared to its average volume of 439,946. Quidel Co. has a 12-month low of $88.37 and a 12-month high of $180.06. The firm has a market cap of $4.86 billion, a price-to-earnings ratio of 7.06 and a beta of -0.10. The stock has a 50 day moving average price of $104.56 and a 200 day moving average price of $123.53.

Quidel (NASDAQ:QDELGet Rating) last issued its quarterly earnings data on Thursday, February 17th. The company reported $7.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $4.77 by $2.40. Quidel had a return on equity of 45.78% and a net margin of 41.46%. The business had revenue of $636.87 million during the quarter, compared to analysts’ expectations of $635.00 million. During the same period in the previous year, the firm posted $10.95 earnings per share. Research analysts anticipate that Quidel Co. will post 15.31 earnings per share for the current fiscal year.

About Quidel (Get Rating)

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye.

Recommended Stories

Institutional Ownership by Quarter for Quidel (NASDAQ:QDEL)

Receive News & Ratings for Quidel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quidel and related companies with MarketBeat.com's FREE daily email newsletter.